ZYNOVATE 0.1% Price

Overview

Welcome to Dwaey, specifically on ZYNOVATE 0.1% Ointment page.
This medicine contains an important and useful components, as it consists of Mometasone furoate.
ZYNOVATE 0.1% is available in the market in concentration 1mg/g and in the form of Ointment.

OMAN PHARMACEUTICAL PRODUCTS is the producer of ZYNOVATE 0.1% and it is imported from OMAN, The most popular alternatives of ZYNOVATE 0.1% are listed downward .

Mode Of Action

Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.

Indication

• Allergic rhinitis
• Nasal polyps
• Asthma prophylaxis

Precaution

Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex Nasal septum perforation, epistaxis, wheezing Cataracts, glaucoma, increased intraocular pressure Risk of more serious or fatal course of chickenpox and measles in susceptible individuals; avoid use in unvaccinated or immunologically unexposed children or adults Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually May retard growth in children Immunocompromised patients Infections of nose and pharynx, including Candida albicans Excessive use may suppress hypothalamic-pituitary-adrenal function During periods of stress or severe status asthmaticus, patient may require supplementary systemic corticosteroids immediately; carry warning card to that effect Long-term administration reduces bone mineral density

Side Effects

• >10% Headache (26%)
• Viral infection (14%)
• Pharyngitis (12%)
• Epistaxis (11%) 1-10% Cough (7%)
• Upper respiratory tract infection (6%)
• Dysmenorrhea (5%) Frequency Not Defined Loss of taste
• Muscle soreness

Contra indication

Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks